公司資料
Dr. Reddy's Laboratories Ltd 股價、新聞與催化劑
- 股票代碼:
- RDY
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- India and listed in the U
股票表現
12.11 USD (-1.30%)
收盤價
最後更新: 2026年8月17日
10.8B USD
市值
股價為何變動
As of Aug 17, 2026, RDY closed down 1.30% at $12.11. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Dr. Reddy’s Laboratories is a global pharmaceutical company with a broad mix of generics, biosimilars, and specialty products. Its business is defined by scale, manufacturing, and a diversified international footprint.
所在地與產業分類
Headquartered in India and listed in the U.S. as an ADR, Dr. Reddy’s has a large global presence across emerging and developed markets. It sits in generics and diversified pharmaceuticals rather than biotech.
商業模式特徵
The company generates value through product volume, manufacturing execution, and portfolio breadth across regulated and emerging markets. Investors watch pricing pressure, product launches, and margin discipline.
生技產業定位
Dr. Reddy’s is not a biotech company, but it is relevant to the broader pharma landscape because it participates in biosimilars and global drug supply. Its stock is driven by manufacturing and commercial execution, not clinical catalysts.
未來催化劑
- Dr. Reddy’s catalysts are US generics execution, biosimilar filings, and continued margin discipline. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。